Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages 1930-1937

  Geinitz, Hans ^a   Riegel, Martina G ^a   Thamm, Reinhard ^a   Astner, Sabrina T ^a   Lewerenz, Carolin ^a   Zimmermann, Frank ^b   Molls, Michael ^a   Nieder, Carsten ^c,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF TROMSØ   (Norway)

^d NORDLAND HOSPITAL   (Norway)

Author keywords

Biochemical relapse; Conformal radiotherapy; Prognostic factors; Prostate cancer; Salvage treatment

Indexed keywords

BIOCHEMICAL RELAPSE; CONFORMAL RADIOTHERAPY; PROGNOSTIC FACTORS; PROSTATE CANCERS; SALVAGE TREATMENT;

ANTIGENS; DISEASES; PATHOLOGY; RADIOTHERAPY;

UROLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SALVAGE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONFORMAL SALVAGE RADIOTHERAPY; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATECTOMY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEMINAL VESICLE; SURVIVAL RATE;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 79958104194     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.03.003     Document Type: Article

References (28)

1. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-4305.
2. Bolla M, van Poppel H, Collette L, et al. Postoperative radio-therapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-578. (Pubitemid 41140332)
3. Thompson IM Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006;296:2329-2335. (Pubitemid 44749360)
4. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/ AUO AP 09/95. J Clin Oncol 2009;27:2924-2930.
5. Boorjian SA, Karnes RJ, Crispen PL, et al. Radiation therapy after radical prostatectomy: Impact on metastasis and survival. J Urol 2009;182:2708-2714.
6. Choueiri TK, Chen MH, D'Amico AV, et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010;116:1887-1892.
7. Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008;72:1298-1302.
8. Jereczek-Fossa BA, Zerini D, Vavassori A, et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2009;74:115-125.
9. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-2041. (Pubitemid 46972788)
10. Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007;84:121-127. (Pubitemid 47284534)
11. Neuhof D, Hentschel T, Bischof M, et al. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 2007;67:1411-1417. (Pubitemid 46467172)
12. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008;71:23-27.
13. Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome - Results of a retrospective study. Int J Radiat Oncol Biol Phys 2009;73:1009-1016.
14. Macdonald OK, D'Amico AV, Sadetsky N, et al. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: From the CaPSURE database. Urol Oncol 2008;26:271-275. (Pubitemid 351608581)
15. Tomita N, Kodaira T, Furutani K, et al. Early salvage radio-therapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol 2009;135:1561-1567.
16. Bernard JR Jr., Buskirk SJ, Heckman MG, et al. Salvage radio-therapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: Dose-response analysis. Int J Radiat Oncol Biol Phys 2010;76:735-740.
17. King CR, Kapp DS. Radiotherapy after prostatectomy: Is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 2008;71:346-350.
18. De Meerleer G, Fonteyne V, Meersschout S, et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol 2008;89:205-213.
19. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-2769. (Pubitemid 351846851)
20. Pai HH, Eldridge B, Bishop D, et al. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Can J Urol 2009;16:4541-4552.
21. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-489. (Pubitemid 46606478)
22. King CR, Presti JC, Gill H, et al. Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004;59:341-347. (Pubitemid 38622584)
23. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007;69:54-61. (Pubitemid 47247505)
24. Parker C, Sydes MR, Catton C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007;99:1376-1379. (Pubitemid 47164815)
25. Yokomizo A, Kawamoto H, Nihei K, et al. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy vs. endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol 2005;35:34-36. (Pubitemid 40450553)
26. Choo R, Danjoux C, Gardner S, et al. Efficacy of salvage radio-therapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys 2009;75:983-989.
27. King CR, Spiotto MT, Kapp DS. Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2009;73:1017-1022.
28. Moreira DM, Jayachandran J, Presti JC Jr., et al. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: Results from the SEARCH database. BJU Int 2009;104:1452-1456.